Skip to content

Serotonin: all studies

Page 253 of 401: studies 2,521 to 2,530 of 4,006, newest first. Back to the serotonin overview

Research

Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction

Research Square February 22, 2024 Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz et al. preprint

Abstract Current treatments for alcohol use disorder (AUD) show large heterogeneity in response and thus limited effectiveness and high relapse rates. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced...

Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.

Molecules February 22, 2024 Hanbo Yao, Xiaodong Wang, Jiaxin Chi et al. 9 citations

Major Depressive Disorder (MDD) is a complex mental disorder that involves alterations in signal transmission across multiple scales and structural abnormalities. The development of effective antidepressants (ADs) has been hindered by the dominance of monoamine hypothesis, resulting in slow progress. Traditional ADs have undesirable traits like delayed onset of action, limited efficacy, and...

Uncovering Structure-Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments.

ACS Chemical Neuroscience February 21, 2024 Sedat Karabulut, Harpreet Kaur, James W Gauld

The rapidly evolving psychedelic industry has garnered considerable attention due to 3,4-methylenedioxymethamphetamine-assisted psychotherapy's ground-breaking success in treating moderate-to-severe Post-traumatic Stress Disorder in two Phase 3 clinical trials. This has opened Pandora's box for the development of innovative therapeutic modalities. Of particular interest are the phenethylamines...

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects.

npj Mental Health Research February 20, 2024 Kush V. Bhatt, Cory R. Weissman 29 citations

Psilocybin is a serotonergic psychedelic shown to have enduring antidepressant effects. Currently, the mechanism for its enduring effects is not well understood. Empathy and prosocial behavior may be important for understanding the therapeutic benefit of psilocybin. In this article we review the effect of psilocybin on empathy and prosocial behavior. Moreover, we propose that psilocybin may...

DOI: 10.1038/s44184-023-00053-8 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Depression treatment Social cognition

[Psychedelics in the field of chronic pain. A path to explore?].

Revue Médicale Suisse February 14, 2024 Aude Molinard-Chenu, Georgios Tsimploulis, Louise Penzenstadler et al.

Psychedelics are emerging as a therapeutic innovation in psychiatry and their use in chronic pain is worth exploring. In fact, they can modulate the serotonergic system, affecting central pain sensitization mechanisms. Ketamine, used for chronic analgesia, can lead to pain reduction, but additional studies are needed to assess its longterm effectiveness. "Classic" psychedelics are recently...

Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.

Biochemistry February 7, 2024 Vito F. Palmisano, Claudio Agnorelli, Andrea Fagiolini et al. 5 citations

High Resolution Image Download MS PowerPoint Slide Renewed scientific interest in psychedelic compounds represents one of the most promising avenues for addressing the current burden of mental health disorders. Classic psychedelics are a group of compounds that exhibit structural similarities to the naturally occurring neurotransmitter serotonin (5-HT). Acting on the 5-HT type 2A receptors (HT...

DOI: 10.1021/acs.biochem.3c00598 (opens in new tab) Full text (opens in new tab) Psychedelics psychedelic tryptamines Hallucinogens Psychoactive drugs Entheogens +10

Effects of DMT on mental health outcomes in healthy volunteers

Scientific Reports February 7, 2024 Christopher Timmermann, Richard J. Zeifman, David Erritzøe et al. 37 citations

Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT), a closely related, but faster-acting...

DOI: 10.1038/s41598-024-53363-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment DMT Research Clinical trials +1

Psychedelics and sexual functioning: a mixed-methods study

Scientific Reports February 7, 2024 Tommaso Barba, Hannes Kettner, Caterina Radu et al. 24 citations

Abstract Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While sexual functioning and satisfaction are generally regarded as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health disorders. It is also a common side effect of selective serotonin reuptake...

DOI: 10.1038/s41598-023-49817-4 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Clinical psychology Sexual dysfunction +2

Lasting dynamic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((±)-DOI) on cognitive flexibility

Molecular Psychiatry February 6, 2024 Merima Šabanović, Alberto Lazari, Marta Blanco-Pozo et al. 17 citations

Abstract Psychedelic drugs can aid fast and lasting remission from various neuropsychiatric disorders, though the underlying mechanisms remain unclear. Preclinical studies suggest serotonergic psychedelics enhance neuronal plasticity, but whether neuroplastic changes can also be seen at cognitive and behavioural levels is unexplored. Here we show that a single dose of the psychedelic...

DOI: 10.1038/s41380-024-02439-2 (opens in new tab) Full text (opens in new tab) Flexibility engineering Cognitive flexibility Cognition Cognitive psychology

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus February 1, 2024 Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al. 13 citations

The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...

DOI: 10.7759/cureus.53987 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression FDA Approval Nmda receptor antagonist Placebo controlled trials +6